ITC Seeks Comments on Section 337 Complaint on Photodynamic Therapy Devices, Drugs
The International Trade Commission seeks comments by July 10 on a Section 337 complaint filed by Sun Pharmaceutical Industries seeking a ban on photodynamic therapy systems and associated pharmaceuticals from Biofrontera that allegedly infringe on its patents. In its June…
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
26 complaint, Sun said Biofrontera’s BF-RhodoLED XL and Ameluz prescription medicines infringe on patents related to Sun’s Blu-U Blue Light Photodynamic Therapy Illuminator device and its Levulan medication. The devices are used “particularly” to treat dermatological conditions, Biofrontera said. The company seeks a limited exclusion order and cease and desist orders banning importation and sale of infringing devices and drugs from Biofrontera.